NCT00001995已完成不适用
A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS
Pharmacia42 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 200
- 试验地点
- 42
研究概览
简要总结
To determine if a drug regimen containing rifabutin will eradicate or decrease the numbers of Mycobacterium avium complex (MAC) organisms in blood, improve the symptoms associated with MAC infection, and increase survival in patients with AIDS. To assess the safety of the drug regimen.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Zidovudine (AZT).
- •Didanosine (ddI).
- •Patients must have the following:
- •Diagnosis of AIDS as defined by the CDC.
- •Blood cultures positive for Mycobacterium avium complex or for acid-fast bacilli (AFB).
- •Provide written informed consent.
- •Prior Medication:
- •If receiving zidovudine (AZT) or ddI must be taking the medication for at least 4 weeks prior to study entry.
- •Required:
- •Antipneumocystis prophylactic therapy for at least 4 weeks prior to study entry.
排除标准
- •Co-existing Condition:
- •Patients with the following conditions or symptoms are excluded:
- •Known hypersensitivity to any of the study drugs.
- •Concurrent Medication:
- •Other therapy for mycobacterial disease.
- •Patients with the following are excluded:
- •Known hypersensitivity to any of the study drugs.
- •Prior Medication:
- •Excluded within 4 weeks:
- •Therapy for mycobacterial disease.
- •Antiretroviral drugs, other than zidovudine (AZT) or ddI.
- •Investigational drugs, other than ddI.
研究者
研究点 (42)
Loading locations...
相似试验
已完成
不适用
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled TrialMycobacterium Avium-intracellulare InfectionHIV InfectionsNCT00002267Pharmacia750
已完成
不适用
Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled TrialMycobacterium Avium-intracellulare InfectionHIV InfectionsNCT00002032Pharmacia750
已完成
3 期
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaLymphomaNCT01855750Janssen Research & Development, LLC838
进行中（未招募）
3 期
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone LymphomaMarginal Zone LymphomaNCT04212013Memorial Sloan Kettering Cancer Center23
终止
2 期
Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected AdultsStaphylococcus AureusHIV InfectionsNCT00869518University of California, San Francisco12